Hypoglycemia Clinical Trial
Official title:
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study
Diabetes technology is changing and has quickly become an integral part of diabetes care and management. The study team plans to study the effects of introducing technology to newly diagnosed type 1 diabetes patients. The investigators hypothesize that early access to continuous glucose monitoring (CGM) technology will potentially improve satisfaction scores, hemoglobin A1c, glycemic control, reduce hypoglycemia, and ease the burden of disease when compared to new onset patients who receive standard of care access to CGM.
Abstract: Diabetes technology is changing and has quickly become an integral part of diabetes
care and management. Typically, patients will need to wait months due to paperwork,
insurance, and logistical issues before utilizing these technologies. With this project, the
investigators plan to study the effects of introducing technology to newly diagnosed type 1
diabetes patients. It is hypothesized that early access to flash continuous glucose
monitoring (CGM) technology will improve scores in diabetes's measures. The primary outcome
with be the parent version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ).
Secondary outcomes will include other diabetes measures such as DTSQ teen version,
Hypoglycemia Fear Survey (HFS)- Parent and child version, Diabetes Distress Survey
(DDS)-parent version, PedsQL- parent and child versions. The study team will also look at
other diabetes outcomes including A1c, time in range, and reduction in hypoglycemia.
Background: Type 1 diabetes is a complex disease requiring newly diagnosed pediatric patients
and families to learn how to check blood glucoses, inject insulin, count carbohydrates, treat
hypoglycemia/hyperglycemia, and perform many other complex tasks, all within the first few
days after diagnosis.
Continuous glucose monitors (CGMs) and flash glucose monitors have emerged as important
diabetes technologies towards providing improved care and easing the burden of disease. These
technologies are most typically introduced to families in the outpatient setting 2-3 months
following diagnosis due to logistical issues related to insurance coverage.
Barriers to access include requirements for insurance prior authorization, lack of immediate
availability at local pharmacies, need for patient training, and the historical bias towards
requiring finger stick glucose monitoring as the basis for diabetes management. Despite these
barriers, the data supports the observation that CGM technology provides for better
understanding of diabetes, improved quality of life for parents and children, reduced
frequency of hypoglycemia, and improved A1c.
This project will potentially show the feasibility of introducing these technologies at
diagnosis. New onset type 1 diabetes patients will be randomized to receive either a
Freestyle Libre flash glucose monitoring system immediately at diagnosis or to delayed use of
CGM (standard of care).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
Completed |
NCT03667053 -
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
|
Phase 3 | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A | |
Not yet recruiting |
NCT05990933 -
Role of Adrenaline in in the Inflammatory Response in Diabetes
|
N/A | |
Not yet recruiting |
NCT02909881 -
Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes
|
N/A | |
Completed |
NCT02966275 -
Post Bariatric Closed Loop Glucagon Trial
|
N/A | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
Completed |
NCT02213003 -
Allogeneic Islet Cells Transplanted Onto the Omentum
|
Phase 1/Phase 2 | |
Completed |
NCT01147276 -
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT01176656 -
Hypoglycemia: Physician and Patient Perspectives
|
N/A | |
Completed |
NCT00998374 -
Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
|
N/A | |
Terminated |
NCT01225159 -
Tight Glycaemic Control During Cardiac Surgery
|
N/A | |
Completed |
NCT00373854 -
Study of How Low Blood Sugar Affects the Way Blood Vessels Work
|
N/A | |
Completed |
NCT00285233 -
Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes
|
Phase 1/Phase 2 | |
Recruiting |
NCT05916131 -
Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.
|
N/A | |
Terminated |
NCT04026750 -
Insulin Tolerance Test Study in Patients With Type 1 Diabetes
|
Phase 1 | |
Completed |
NCT05133765 -
The SMART B Exercise Study :''The SMART Study''
|
N/A | |
Recruiting |
NCT04192422 -
DiGESTnewborn Study
|